Top news of November: FDA oral phenylephrine removal, anaphylaxis, epinephrine, more
Click Here to Manage Email Alerts
Healio has compiled November’s most read news in asthma and allergy.
Top stories included breaking FDA news about the discontinuation of using oral phenylephrine in nasal decongestants, reports from our Women in Allergy series, challenges in anaphylaxis diagnosing, updates on the sublingual epinephrine film and more.
FDA proposes removing oral phenylephrine from nasal decongestants
The FDA has proposed an order for the removal of oral phenylephrine as an active ingredient from over-the-counter monograph drug products for relieving nasal congestion. The proposal is based on the drug’s efficacy, not its safety. Douglas H. Jones, MD, and Zachary E. Rubin, MD, weigh in on this decision. Read more.
Physicians encouraged to conduct oral food challenges for infants, toddlers
Physicians should not hesitate to conduct oral food challenges for infants and toddlers, Aikaterini (Katherine) Anagnostou, MD, MSc, PhD,FACAAI, said during the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Communication can help families prepare for a successful challenge. Read more.
‘We have a home’: Physician aims to create network of women allergists
Priya J. Bansal, MD, FAAAAI, FACAAI, wants to minimize burdens on providers and improve patient care nationwide. She told Healio about how she is using her platform to create a community of women allergists as part of our Women in Allergy series. Read more.
Challenges remain in anaphylaxis diagnosis despite consensus criteria
Consensus criteria for anaphylaxis diagnosis are moving toward more objective assessments of symptoms, Julia Upton, MD, MPH, explained during the ACAAI Annual Scientific Meeting. She emphasized discrepancies between diagnosis guidelines from major organizations. Read more.
Health-seeking behaviors improve allergic rhinitis
Encouraging health-seeking behaviors could expedite recovery for patients with allergic rhinitis, according to a poster presented by Atoosa Kourosh, MD, MPH, RYT, at the ACAAI Annual Scientific Meeting. “Allergy practitioners have come to realize that anxiety and depression and mental health interplays with allergic rhinitis,” she told Healio. Read more.
Allergen-related symptoms resolve within 5 minutes with epinephrine sublingual film
Allergen-related symptoms resolved within 5 minutes after an oral allergen challenge with the Anaphylm sublingual epinephrine strip from Aquestive Therapeutics, according to a press release from the company. Daniel Barber, MBA, and Carl Kraus, MD, FACP, explain what this means for patients and practitioners. Read more.
Inaccurate pediatric penicillin allergy labels successfully delabeled
Delabeling inappropriate penicillin allergy labels in outpatient pediatric patients is feasible, according to an abstract presented at the American Academy of Pediatrics National Conference & Exhibition. Out of 121 patients, 14 were delabeled in a primary care office and 13 were delabeled with an allergist. Read more.
Physicians encouraged to ‘embrace’ technology in practice management
Physicians should make technology work for them and not be afraid of it, Priya J. Bansal, MD, FAAAAI, FACAAI, said during her presentation on optimizing workflow at the ACAAI Annual Scientific Meeting. Things such as real-time benefit checks may improve the prior authorization process among other methods to streamline care. Read more.
Q&A: Physician aspires to improve outcomes for underserved communities
In October, Healio announced Aisha Mohammed, MD, as a 2024 honoree of its peer-to-peer recognition program, Healio Honors. She told Healio about the need to address social determinants of health and placed emphasis on staying informed about new research, treatments and patient care strategies as part of our Women in Allergy series. Read more.
Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial
IgGenix announced the first patient dosed with IGNX001, a monoclonal antibody-based therapeutic for peanut allergy. Healio spoke with Jessica Grossman, MD, CEO of IgGenix, about IGNX001 and what it means for patients with peanut allergies. Read more.